Plus Therapeutics (NASDAQ:PSTV) Shares Up 0.6% – Still a Buy?

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) shot up 0.6% on Thursday . The stock traded as high as $3.69 and last traded at $3.65. 51,978 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 120,239 shares. The stock had previously closed at $3.63.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on PSTV shares. Ascendiant Capital Markets lowered their price objective on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $56.40.

Plus Therapeutics Trading Up 6.0%

The company has a market cap of $26.63 million, a PE ratio of -1.68 and a beta of 1.40. The firm has a 50 day moving average of $4.56 and a two-hundred day moving average of $5.74.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings data on Friday, May 15th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.97 million. On average, research analysts forecast that Plus Therapeutics, Inc. will post -3.76 EPS for the current year.

Hedge Funds Weigh In On Plus Therapeutics

Hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in Plus Therapeutics in the fourth quarter worth about $254,000. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics during the fourth quarter valued at approximately $525,000. Geode Capital Management LLC increased its position in shares of Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after acquiring an additional 589,544 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Plus Therapeutics during the fourth quarter valued at approximately $127,000. Finally, State Street Corp raised its holdings in Plus Therapeutics by 37.1% in the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after acquiring an additional 127,000 shares during the last quarter. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.